

Norimitsu Kasahara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/943606/publications.pdf>

Version: 2024-02-01

14
papers

186
citations

1478505

6
h-index

1199594

12
g-index

15
all docs

15
docs citations

15
times ranked

297
citing authors

#	ARTICLE	IF	CITATIONS
1	Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma. Lung Cancer, 2018, 119, 71-77.	2.0	46
2	Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2020, 85, 761-771.	2.3	32
3	Post-treatment Glasgow Prognostic Score Predicts Efficacy in Advanced Non-small-cell Lung Cancer Treated With Anti-PD1. Anticancer Research, 2019, 39, 1455-1461.	1.1	31
4	Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer. Lung Cancer, 2019, 134, 180-186.	2.0	25
5	Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer. Cancers, 2021, 13, 5956.	3.7	13
6	Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment. Thoracic Cancer, 2020, 11, 2188-2195.	1.9	11
7	Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study. Supportive Care in Cancer, 2020, 28, 4825-4831.	2.2	8
8	Dual inhibition of MEK and p38 impairs tumor growth in KRAS-mutated non-small cell lung cancer. Oncology Letters, 2019, 17, 3569-3575.	1.8	6
9	Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥75 years) with non-small cell lung cancer: A retrospective analysis. Thoracic Cancer, 2020, 11, 2867-2876.	1.9	4
10	Successful afatinib rechallenge in a patient with non-small cell lung cancer harboring EGFR G719C and S768I mutations. Thoracic Cancer, 2020, 11, 2351-2356.	1.9	4
11	Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer. Translational Cancer Research, 2019, 8, S628-S632.	1.0	3
12	A case of a patient with neurofibromatosis type I who developed pneumothorax and eosinophilic pleural effusion after suffering from COVID-19 pneumonia. Radiology Case Reports, 2021, 16, 3504-3508.	0.6	3
13	Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC. Anticancer Research, 2020, 40, 1571-1578.	1.1	0
14	Association of ¹⁸ F-FDG uptake on PET with PD-L1 expression in patients with non-small cell lung cancer. Journal of Clinical Oncology, 2018, 36, e24138-e24138.	1.6	0